Blog

  • Autism in Adults: Presentation, Diagnosis, and Management

    Autism in Adults: Presentation, Diagnosis, and Management

    Autism spectrum disorder (ASD) is a neurodevelopmental disorder that affects an individual’s social interactions and communication.1 In recent decades, the prevalence of ASD has increased from 1 in every 150 children to 1 in every 36.2 While most people with ASD are diagnosed during childhood, individuals with ASD who have subtle symptoms and/or are able to use compensation strategies and coping mechanisms may not receive a diagnosis until adulthood.1 Many of the diagnostic criteria, diagnostic tests, and interventions for ASD emphasize children. Understanding how to recognize, diagnose, and manage ASD in adults is critical to being able to provide optimal care for these patients.

    Autism Spectrum Disorder Diagnostic Criteria

    As described in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), the diagnostic criteria for ASD include 5 main components1:

    1. Persistent deficits in social communication and social interaction;
    2. Restricted, repetitive patterns of behavior, interests, or activities;
    3. Symptoms must be present in the early developmental period; 
    4. Symptoms must cause clinically significant impairment in social, occupational, or other important areas of functioning; and
    5. These disturbances are not better explained by intellectual disability or global developmental delay.

    Social Deficits

    The social deficits of ASD are categorized as difficulties with social-emotional reciprocity, nonverbal communication, and relationships. Social-emotional reciprocity impairments include having difficulty initiating conversations, being unable to carry on a typical back-and-forth conversation, and not responding in emotionally sensitive or appropriate ways.1 Nonverbal communication deficits include trouble making eye contact or using body language, difficulty using or understanding gestures, and a lack of facial expressions.1 Individuals with ASD may have a lack of interest in or trouble making friends and maintaining friendships. They also may have trouble adjusting their behavior to suite various social contexts.1

    Restricted, Repetitive Behaviors

    Behaviors that are characteristic of ASD include the following1:

    • Repetitive motor movements (such as hand flapping or finger flicking), use of objects (such as spinning coins), and speech (such as repeating words and phrases used by others);
    • Rigid adherence to schedules and resistance to change;
    • Having highly restricted, fixated interests; and 
    • Exhibiting increased sensitivity to sensory stimuli.

    For a patient to meet the criteria for an ASD diagnosis, these symptoms need to have been present since early development.1 Although the ASD symptoms may not become fully evident until later in life, ASD does not first develop in adulthood.1 The ASD diagnostic criteria in DSM-V require that deficits limit or impair a person’s everyday functioning, such as the ability to excel in school, maintain a job, or live independently.1

    Symptoms of Autism in Adults

    Adults with ASD generally have similar signs and symptoms as children. These usually center around poor communication strategies and impaired social functioning. However, adults with ASD may have learned to “mask” or cover up some of those symptoms to fit in and shield themselves from social repercussions associated with ASD. Behaviors that might be used to mask ASD symptoms include the following3,4:

    • Mimicking others’ mannerisms and styles; 
    • Mimicking small talk; 
    • Altering speech volume;
    • Rehearsing conversation topics before interacting with others;
    • Making eye contact despite discomfort doing so; and
    • Not standing too close to others. 

    Masking ASD traits may be more prevalent in females than in males.4 One reason more males than females are diagnosed with ASD earlier in life may be that females have more effective masking strategies.4 Masking can help individuals with ASD to succeed in social situations, but it can also lead to anxiety and exhaustion.4 

    Examples of potential symptoms of ASD in adults include the following3:

    • Difficulty with expressive communication: Lack of a filter when speaking, flat affect, monotonous tone of voice, difficulty maintaining conversations, avoidance of or particularly intense eye contact, difficulty identifying thoughts/feelings;
    • Difficulty interpreting communication: Trouble understanding nonverbal cues and others’ intentions, thoughts and feelings; and 
    • Restricted interests and behaviors: Insistence on routine and stress when routines are disrupted, intense interest in a particular hobby, object, or area of study.

    In terms of repetitive behaviors, adults with ASD often learn to hide hand flapping and other motor movements that are characteristic of younger patients, but they may adapt such behaviors by rubbing their fingers together inside a pocket, tapping their feet, or repetitively rubbing their hands on their thighs.3 In adults, some internal symptoms might not be outwardly apparent, such as social anxiety, social phobia, or exhaustion after social activities3 Adults with ASD also may3:

    • Have trouble organizing, planning, or maintaining focus;
    • Irregular sleep patterns; and
    • Clumsy gait or poor physical coordination.

    Diagnosing Autism in Adults

    Challenges to accurately diagnosing ASD in an adult include the need to determine if symptoms were present during the patient’s early development period, an adult’s ability to mask or compensate for ASD symptoms, and the high rates of co-occurring psychiatric and medical disorders, with symptoms overlapping those of ASD.5,6 Prompt diagnosis is important because even in adults, earlier diagnosis is associated with improved quality of life.7 The optimal approach to diagnosing ASD in an adult has not yet been established. A request for evaluation for ASD may be initiated by the patient or by a family member/caregiver. The clinician may need to talk to the patient’s family members to determine if symptoms of ASD have been present since the patient’s childhood.8 A referral to a psychiatrist or neuropsychiatrist who specializes in ASD often is necessary because those clinicians are best equipped to make the diagnosis.3,8

    The DSM-5-TR diagnostic criteria for ASD are used for both children and adults. However, additional measures may be needed to help establish an accurate diagnosis in an adult patient. Questionnaires used to help clarify an ASD diagnosis in adults include the Autism Spectrum Quotient (AQ), the abridged AQ-10, the Social Responsiveness Scale-Adult version, and the second edition of the Autism Diagnostic Observation Schedule (ADOS-2).6

    The ADOS-2 is considered a gold-standard instrument for diagnosing ASD in adults.5 It’s a standardized test for measuring communication deficits. It consists of 4 modules that can be administered based on the patient’s age; module 4 is intended for adolescents and adults with fully developed speech.5 

    The ADOS-2 focuses on verbal and nonverbal communication deficits. The test is highly sensitive —  it does a good job of detecting ASD in adults who actually have the condition — but there are many false positives, especially if the patient has psychotic symptoms.5 

    Management of Autism in Adults

    Treatment of ASD specifically for adults remains poorly studied, and services for adults with ASD lag far behind those available for children.9 Optimized treatment strategies have not been established.6 Autism spectrum disorder in adulthood presents heterogeneously, and treatment strategies are mostly individually based. 

    Psychosocial Interventions

    Behavioral-based treatments such as social skills training and applied behavior analysis have been used to effectively address the core symptoms of ASD in children, and may be appropriate for adults.4,6 Cognitive-behavior therapy and mindfulness-based therapy approaches have been used with some success for adults with ASD.6 These strategies have been used to improve communication as well as emotional processing to reduce anxiety and stress that arise from societal and social expectations that are not intuitive to understand.4,6 Vocational support such as training in interview skills and supported employment may be beneficial for adults with ASD but research to support a specific vocational strategy is lacking.6

    Receiving an ASD diagnosis as an adult can be overwhelming. It is important for adults with ASD to have access to support and resources to understand their condition and feel less isolated. Support groups can be useful for the patient as well as for the family members of an adult who has been recently diagnosed with ASD.3 Online support groups can allow patients to share their experiences without having to face the anxiety of in-person interactions.3

    Pharmacotherapy

    Other than the antipsychotics aripiprazole and risperidone for treating ASD-associated irritability in children of certain ages, the US Food and Drug Administration has not approved any medications for treating ASD.10 However, people with ASD often also have comorbid psychiatric symptoms and disorders, and receive medication to address these conditions. Specifically, an adult with ASD may benefit from being prescribed the following medications6: 

    • Stimulants or atomoxetine for attention-deficit/hyperactivity disorder;
    • Antidepressants for anxiety, depression, or obsessive-compulsive disorder;
    • Mood stabilizers for bipolar disorder; or
    • Antipsychotics for irritability and impulsivity. 

    Author Bio

    Hannah Actor-Engel, PhD, earned a BS in Neural Science at New York University and her PhD in Neuroscience at the University of Colorado. She is a multidisciplinary neuroscientist who is passionate about scientific communication and improving global health through biomedical research

  • Johnson & Johnson (JNJ) earnings Q1 2024

    Johnson & Johnson (JNJ) earnings Q1 2024

    An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019.

    Mark Ralston | AFP | Getty Images

    Johnson & Johnson on Tuesday reported first-quarter adjusted earnings that topped Wall Street’s expectations as sales in its medical devices business surged.

    Meanwhile, the company’s total revenue for the period was largely in line with estimates.

    J&J’s medtech division provides devices for surgeries, orthopedics and vision. The company is benefiting from a rebound in demand for nonurgent surgeries among older adults, who deferred those procedures during the Covid pandemic. That increased demand has been observed by health insurers like Humana, UnitedHealth Group and Elevance Health.

    J&J CFO Joseph Wolk told CNBC’s “Squawk Box” on Tuesday that consumers may be pulling back in other areas but “don’t want to compromise when it comes to their health, their mobility, their ability to live a fulfilling life.” He added that the company has seen elevated procedure levels after the pandemic, and “we haven’t seen any backtracking of that.”

    Still, shares of the company closed more than 1% lower on Tuesday.

    Here’s what J&J reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:

    • Earnings per share: $2.71 adjusted vs. $2.64 expected
    • Revenue: $21.38 billion vs. $21.4 billion expected

    J&J’s financial results are considered a bellwether for the broader health sector.

    The company posted $21.38 billion in total sales for the first three months of 2024, up more than 2% from the same quarter in 2023. 

    The pharmaceutical giant booked net income of $5.35 billion, or $2.20 per share during the quarter. That compares with a net loss of $491 million, or 19 cents per share, for the year-earlier period. At the time, J&J recorded costs tied to its talc baby powder liabilities and the spinoff of its consumer health unit Kenvue

    Excluding certain items for the first quarter of 2024, adjusted earnings per share were $2.71.

    J&J also narrowed its full-year guidance for the year. The company now expects sales of $88 billion to $88.4 billion. That compares with a previous forecast of $87.8 billion to $88.6 billion. 

    J&J expects adjusted earnings of $10.57 to $10.72 per share. That compares to a previous guidance of $10.55 to $10.75 per share.

    Separately on Tuesday, J&J said it will increase its quarterly dividend to $1.24 per share, up 4.2% from $1.19 per share. That marks the company’s 62nd year of consecutive dividend increases, it said. The dividend is payable on June 4.

    Medical device unit

    The results come weeks after J&J’s whopping $13.1 billion acquisition of heart device firm Shockwave Medical — part of its push into the cardiovascular space. Both companies have said the deal will make J&J a leader in four quickly growing cardiovascular technology categories. 

    J&J expects the transaction to close in the middle of the year, which will impact the company’s full-year guidance, executives said during an earnings call on Tuesday.

    J&J has scooped up two other heart device companies over the last two years, spending $16.6 billion to buy Abiomed and $400 million to acquire private company Laminar. 

    Those deals also aim to strengthen J&J’s medical devices business after the company’s separation from its consumer health unit Kenvue last year.

    J&J’s medical devices business generated sales of $7.82 billion during the first quarter, up more than 4% year over year. Wall Street was expecting revenue of $7.87 billion, according to estimates compiled by StreetAccount.

    J&J said its acquisition of Abiomed fueled the year-over-year rise. The growth also came from electrophysiological products, which evaluate the heart’s electrical system and help doctors understand the cause of abnormal heart rhythms, according to J&J. 

    Wound closure products and devices for orthopedic trauma, or serious injuries of the skeletal or muscular system, also contributed. 

    But sales of the unit’s vision products, including contact lenses, fell 3.3% to $1.26 billion in the quarter. Wall Street was expecting vision sales of $1.33 billion. 

    During the call, J&J executives said that was primarily driven by a “contraction” of U.S. distributor inventory in contact lenses. But they added that the company expects single-digit growth in vision this year and is confident that there will be “tremendous improvement in the performance of that business” moving forward.

    Other segments

    Meanwhile, J&J reported $13.56 billion in pharmaceutical sales, marking around 1% year-over-year growth. Excluding sales of its unpopular Covid vaccine, revenue in the pharmaceutical division grew almost 7%.

    It was the fourth quarter without any U.S. sales from J&J’s Covid vaccine, which brought in $25 million in international revenue.

    Analysts were expecting sales of $13.5 billion for the business segment, according to StreetAccount. The business, also known as “Innovative Medicine,” is focused on developing drugs across different disease areas.

    More CNBC health coverage

    The company said the growth was driven by sales of Darzalex, a biologic for the treatment of multiple myeloma, and Erleada, a prostate cancer treatment. J&J’s Carvykti, a cell therapy approved for a certain blood cancer, and other oncology treatments also contributed to the rise.

    But first-quarter sales of the company’s blockbuster drug Stelara, which is used to treat several chronic and potentially disabling conditions such as Crohn’s disease, were relatively flat from the same period a year ago.

    Stelara brought in $2.45 billion in sales for the quarter. Wall Street was expecting revenue of $2.61 billion.

    J&J began to lose patent protections on Stelara late last year, which opened up the door for cheaper biosimilar competitors to enter the market. But the company has signed settlement agreements with Amgen and other drugmakers to delay the launch of some Stelara copycats to 2025.

    Talc liabilities

    J&J’s first-quarter results come amid investor anxiety over the tens of thousands of lawsuits claiming that the company’s talc-based products were contaminated with the carcinogen asbestos and caused ovarian cancer and several deaths.

    Those products, which include J&J’s namesake baby powder, now fall under Kenvue. But J&J will assume all talc-related liabilities that arise in the U.S. and Canada.

    Notably, a federal judge ruled in March that J&J can contest scientific evidence that links its talc products to ovarian cancer, which could potentially disrupt a federal court case that consolidates 53,000 lawsuits.

    Wolk on Tuesday called that ruling a “very significant development” and said the evidence being brought against J&J is “junk science.” But he noted that it’s difficult to provide a timeline for when the company will reach a broad resolution for the ongoing litigation.

    In January, J&J said it has reached a tentative settlement to resolve an investigation by more than 40 states into claims the company misled patients about the safety of its talc-based products. The company will pay $700 million to settle the probe, Wolk told The Wall Street Journal at the time.

    Last year, J&J set aside about $400 million to resolve U.S. state consumer protection claims.

    Notably, the settlement does not resolve the lawsuits, some of which are slated to go to trial this year. 

    Don’t miss these exclusives from CNBC PRO

  • Why Opioid Settlement Money Is Paying County Employees’ Salaries

    Why Opioid Settlement Money Is Paying County Employees’ Salaries

    More than $4.3 billion in opioid settlement money has landed in the hands of city, county and state officials to date — with billions more on the way. But instead of using the cash to add desperately needed treatment, recovery and prevention services, some places are using it to replace existing funding.

    Local officials say they’re trying to stretch tight budgets, especially in rural areas. But critics say it’s a lost opportunity to bolster responses to an ongoing addiction crisis and save lives.

    “To think that replacing what you’re already spending with settlement funds is going to make things better — it’s not,” said Robert Kent, former general counsel for the Office of National Drug Control Policy. “Certainly, the spirit of the settlements wasn’t to keep doing what you’re doing. It was to do more.”

    The debate is playing out in Scott County, Ind. The rural community made headlines in 2015 after intravenous drug use led to a massive HIV outbreak and then-Gov. Mike Pence (R) legalized syringe service programs. (The county has since shuttered its syringe program.) 

    In 2022, the county received more than $570,000 in opioid settlement funds. It spent about 45 percent of that on salaries for its health director and emergency medical services staff, according to reports it filed with the state. The money usually budgeted for those salaries was freed to buy an ambulance and create a rainy-day fund for the health department.

    In public meetings, Scott County leaders said they hoped to reimburse the departments for resources they dedicated to the HIV outbreak years ago. 

    Their conversations echo the struggles of other rural counties, which have tight budgets in part because for years they poured money into combating the opioid crisis. Now they want to recoup some of those expenses.

    But many families affected by addiction, recovery advocates, and legal and public health experts say that misses the point, that the settlements were aimed at helping the nation make progress against the overdose epidemic.

    Thirteen states and Washington, D.C., have restricted substituting opioid settlement funds for existing government spending, according to state guides created by OpioidSettlementTracker.com and the public health organization Vital Strategies. A national set of principles created by Johns Hopkins University also advises against the practice, known as supplantation.

    But it’s happening anyway. 

    County commissioners in Blair County, Pa., used about $320,000 of settlement funds for a drug court that has been operating with other sources of money for more than two decades, according to a report the county filed with a state council overseeing settlement funds.

    In New York, some lawmakers and treatment advocates say the governor’s proposed budget substitutes millions of opioid settlement dollars for a portion of the state addiction agency’s normal funding.

    Given the complexities of state and local budgets, it’s often difficult to spot supplantation. But one place to start is identifying how much opioid settlement money your community has received so far. Use our searchable database to find out. Then ask elected officials how they’re spending those dollars. In many places, dedicated citizens are the only watchdogs for this money.

    If you discover anything interesting, shoot me a note.


    This article is not available for syndication due to republishing restrictions. If you have questions about the availability of this or other content for republication, please contact [email protected].


  • Fighting Cancer and the Common Cold with Garlic 

    Fighting Cancer and the Common Cold with Garlic 

    Raw garlic is compared to roasted, stir-fried, simmered, and jarred garlic.

    Garlic lowers blood pressure, regulates cholesterol, and stimulates immunity. I’ve talked before about its effect on heart disease risk factors, but what about immunity? Eating garlic appears to offer the best of both worlds, dampening the overreactive face of the immune system by suppressing inflammation while boosting protective immunity—for example, the activity of our natural killer cells, which our body uses to purge cells that have been stricken by viruses or cancer. “In World War II garlic was called ‘Russian Penicillin’ because, after running out of antibiotics, the soviet government turned to these ancient treatments for its soldiers,” but does it work? You don’t know until you put it to the test.

    How about preventing the common cold? As I discuss in my video Benefits of Garlic for Fighting Cancer and the Common Cold, it is perhaps “the world’s most widespread viral infection, with most people suffering approximately two to five colds per year.” In the first study “to use a double-blind, placebo-controlled design to investigate prevention of viral disease with a garlic supplement,” those randomized to the garlic suffered 60 percent fewer colds and were affected 70 percent fewer days. So, those on garlic not only had fewer colds, but they also recovered faster, suffering only one and a half days instead of five. Accelerated relief, reduced symptom severity, and faster recovery to full fitness. Interesting, but that study was done about two decades ago. What about all of the other randomized controlled trials? There aren’t any. There’s only that one trial to date. Still, the best available balance of evidence suggests that, indeed, “garlic may prevent occurrences of the common cold.”

    What about cancer? Is garlic “a stake through the heart of cancer?” As you can see below and at 2:05 in my video, various garlic supplements have been tested on cells in a petri dish or lab animals, but there weren’t any human studies to see if garlic could affect gene expression until now. 

    Researchers found that if you eat one big clove’s worth of crushed raw garlic, you get an alteration of the expression of your genes related to anti-cancer immunity within hours. You can see a big boost in the production of cancer-suppressing proteins like oncostatin when you drip garlic directly on cells in a petri dish, as shown in the graph below and at 2:25 in my video.   

    What’s more, you can also see boosted gene expression directly in your bloodstream within three hours of eating it, as seen below and at 2:34 in my video. Does this then translate into lower cancer risk?

    As you can see in the graph below and at 2:44 in my video, after putting together ten population studies, researchers found that those reporting higher consumption of garlic only had half the risk of stomach cancer.

    How do you define “high” garlic consumption? Each study was different, from a few times a month to every day. Regardless, those who ate more garlic appeared to have lower cancer rates than those who ate less, suggesting a protective effect. Stomach cancer is a leading cause of cancer-related death around the world, and garlic “is relatively cheap; the product is freely available and easy to incorporate into a daily diet in a palatable manner”—and safely, too, so why not? And, perhaps, the more, the better. 

    The only way to prove garlic can prevent cancer is to put it to the test. Thousands of individuals were randomized to receive seven years of a garlic supplement or a placebo. Those getting garlic did tend to get less cancer and die from less cancer, as you can see below and at 3:35 in my video, but the findings were not statistically significant, meaning that could have just happened by chance. 

    Why didn’t we see a more definitive result, given that garlic eaters appear to have much lower cancer rates? Well, the researchers didn’t give them garlic; they gave them garlic extract and oil pills. It’s possible that some of the purported active components weren’t preserved in supplement form. Indeed, one study of garlic supplements, for example, found that it might take up to 27 capsules to obtain the same amount of garlic goodness found in just half a clove of crushed raw garlic.  

    What happens if you cook garlic? If you compare raw chopped garlic to garlic simmered for 15 minutes, boiled for 6 minutes, or stir-fried for just 1 minute, you can get a three-fold drop in one of the purported active ingredients called allicin when you boil it, even more of a loss if you simmer it too long, and seemingly total elimination by even a single minute of stir-frying, as seen below and at 4:21 in my video. What about roasted garlic? Surprisingly, even though roasting is hotter than boiling, that cooking method preserved about twice as much. Raw garlic has the most, but it may be easier for some folks to eat two to three cloves of cooked garlic than even half a clove of raw. 

    What about pickled garlic or those jars of minced garlic packed in water or oil? Fancy, fermented black garlic? Though jarred garlic may be more convenient, they have comparatively less garlicky goodness, especially pickled garlic, and the black garlic falls far behind, as you can see in the graph below and at 5:12 in my video

    Can you eat too much? The garlic meta-analysis suggests there are no real safety concerns with side effects or overdosing, though that’s with internal use. You should not stick crushed garlic on your skin. It can cause irritation and, if left on long enough, can actually burn you. Wrap your knees with a garlic paste bandage or stick some on your back overnight, and you can end up burned, as seen below, and at 5:42 and 5:44 in my video.  

    Definitely don’t rub garlic on babies, even if you see an online article saying that topical garlic is good for respiratory disorders and your little one is congested. Below and at 5:57 in my video, you can see the blisters she got. The poor pumpkin! “It is crucial…to explain to patients that ‘natural’ does not equal ‘safe’…” 

    Don’t put it on your toes, don’t use it as a face mask, and don’t use it to try to get out of military service either.  

    If you just eat it like you’re supposed to, there shouldn’t be a problem. Some people can get an upset stomach if they eat too much, though, and you can’t really say there aren’t any side effects, given the “body odor and bad breath.”

    The other video I mentioned is Friday Favorites: Benefits of Garlic Powder for Heart Disease. What else can garlic do? See related posts below.

    And, for more on specific foods for fighting colds and cancer, check out related posts below. 

  • Lawsuit Alleges Obamacare Plan-Switching Scheme Targeted Low-Income Consumers

    Lawsuit Alleges Obamacare Plan-Switching Scheme Targeted Low-Income Consumers

    A wide-ranging lawsuit filed Friday outlines a moneymaking scheme by which large insurance sales agency call centers enrolled people into Affordable Care Act plans or switched their coverage, all without their permission.

    According to the lawsuit, filed in U.S. District Court for the Southern District of Florida, two such call centers paid tens of thousands of dollars a day to buy names of people who responded to misleading advertisements touting free government “subsidies” and other rewards. In turn, sales agents used the information to either enroll them in ACA plans or switch their existing policies without their consent.

    As a result, the lawsuit alleges, consumers lost access to their doctors or medications and faced financial costs, such as owing money toward medical care or having to repay tax credits that were paid toward the unauthorized coverage.

    Some consumers were switched multiple times or had duplicative policies.

    “We allege there was a plan that targeted the poorest of Americans into enrolling in health insurance through deceptive ads and unauthorized switching,” to gain compensation for the sign-ups or capture the commissions that would have been paid to legitimate insurance agents, said Jason Doss, one of two lawyers who filed the case following a four-month investigation.

    Doss and Jason Kellogg, the other lawyer on the case, which was filed on behalf of several affected policyholders and agents, are seeking class action status.

    KFF Health News has in recent weeks reported on similar concerns raised by consumers and insurance agents.

    Named as defendants are TrueCoverage and Enhance Health, which operate insurance call centers in Florida and other states; Speridian Technologies, a New Mexico-based limited liability company that owns and controls TrueCoverage; and Number One Prospecting, doing business as Minerva Marketing, which is also a lead-generating company. The lawsuit also names two people: Brandon Bowsky, founder and CEO of Minerva; and Matthew Herman, CEO of Enhance Health. Attempts to reach the companies for comment were unsuccessful.

    According to the lawsuit, the call centers had access to policyholder accounts through “enhanced direct enrollment” platforms, including one called Benefitalign, owned by Speridian.

    Such private sector platforms, which must be approved by the Centers for Medicare & Medicaid Services, streamline enrollment by integrating with the federal ACA marketplace, called healthcare.gov. The ones included in this case were not open to the public, but only to those call center agencies granted permission by the platforms.

    One of the plaintiffs, Texas resident Conswallo Turner, signed up for ACA coverage in December through an agent she knew, and expected it to go into effect on Jan. 1, according to the lawsuit. Not long after, Turner saw an ad on Facebook promising a monthly cash card to help with household expenses.

    She called the number on the ad and provided her name, date of birth, and state, the lawsuit says. Armed with that information, sales agents then changed her ACA coverage and the agent listed on it five times in just a few weeks, dropping coverage of her son along with way, all without her consent.

    She ended up with a higher-deductible plan along with medical bills for her now-uninsured son, the lawsuit alleges. Her actual agent also lost the commission.

    The lawsuit contains similar stories from other plaintiffs.

    The routine worked, it alleges, by collecting names of people responding to online and social media ads claiming to offer monthly subsidies to help with rent or groceries. Those calls were recorded, the suit alleges, and the callers’ information obtained by TrueCoverage and Enhance Health.

    The companies knew people were calling on the promise “of cash benefits that do not exist,” the lawsuit said. Instead, call center agents were encouraged to be “vague” about the money mentioned in the ads, which was actually the subsidies paid by the government to insurers toward the ACA plans.

    The effort targeted people with low enough incomes to qualify for large subsidies that fully offset the monthly cost of their premium, the lawsuit alleges. The push began after March 2022, when a special enrollment period for low-income people became available, opening up a year-round opportunity to enroll in an ACA plan.

    The suit asserts that those involved did not meet the privacy and security rules required for participation in the ACA marketplace. The lawsuit also alleges violations of the federal Racketeer Influenced and Corrupt Organizations Act, known as RICO.

    “Health insurance is important for people to have, but it’s also important to be sold properly,” said Doss, who said both consumers and legitimate agents can suffer when it’s not.

    “It’s not a victimless crime to get zero-dollar health insurance if you don’t qualify for it and it ends up causing you tax or other problems down the road,” he said. “Unfortunately, there’s so much fraud that legitimate agents who are really trying to help people are also being pushed out.”

  • ‘Good friction:’ Experts share how artificial intelligence works in their office

    ‘Good friction:’ Experts share how artificial intelligence works in their office

    April 15, 2024

    3 min read

    Add topic to email alerts

    Receive an email when new articles are posted on

    Please provide your email address to receive an email when new articles are posted on .


    data-action=”subscribe”>
    Subscribe

    We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

    Back to Healio

    Key takeaways:

    • Replacing answering services and paper forms with AI can improve patient and provider satisfaction.
    • Choosing technology that integrates with your EHR is crucial.

    DENVER — Incorporating artificial intelligence into daily practice can benefit both providers and patients, according to experts here at the American Academy of Neurology annual meeting.

    In a panel discussion, Louis A. Tramontozzi, III, MD, a neurologist in private practice at North Shore Neurology in Massachusetts, detailed how his team has implemented several AI-related tools to improve provider and staff productivity and wellbeing, while generating cost savings and a positive impact on patient satisfaction.

    A panel of experts weighed in on the benefits of AI in daily practice. Image: Adobe Stock

    Tramontozzi’s practice, which consists of about nine providers, receives up to 800 patient phone calls per day and 20 voicemails per hour. This call volume was the impetus, he said, to firing their answering service and hiring a robot. Now, when a patient leaves a voicemail, the audio is immediately and automatically transcribed and input into the patient’s chart and assigned to a staff member.

    “This has allowed us to keep the patients front and center, so our staff are interacting with patients instead of being on the phone. And they’re able to turn around some phone calls, our record is in 2 to 5 minutes, which is unbelievable,” he said. “It’s helped our staff to feel more empowered as well, and that they’re valued more [because] the work they’re actually doing is much more meaningful than listening to voicemails and transcribing.”

    Panelist Leeann Garms, chief executive officer of Raleigh Neurology Associates in North Carolina, said this type of AI has the potential to create “good friction” in the system because patients and providers are interacting in a more meaningful way. For those in a position to make this switch, Garms suggested starting with night calls, then migrating to daytime calls if it makes sense for your practice.

    “With any change, it’s all about messaging,” Tramontozzi said. He suggested practices make patients aware of changes — like those implemented with the voicemail software — via an email blast to portal members, or as part of the provider’s script at the end of new patient visits.

    Patient intake and consent forms are another area that has been improved by AI for both Tramontozzi and Garms. One year ago, new patients in Tramontozzi’s practice were handed a clipboard, pen and various intake and consent forms, which were often only partially completed, if at all. Then, staff were tasked with prepping and inputting all the information into the electronic health record, a job they hated, he said. Now, new patients receive secure text messages with intake paperwork and consent forms to be filled out prior to their visit, and the information patients provide is automatically populated in their chart. If this system presents a challenge, the practice has iPads at the office that can be used to assist the patients.

    “Our staff are no longer prepping,” Tramontozzi said. “They’re much happier and we have a higher chance of retaining them and getting them back to meaningful work, and that is really empowering for all of us no matter what job we have.”

    Another bonus for Tramontozzi is that for simpler patient visits, the history of present illness, or HPI, is essentially written for him based on the information the patient provides during intake. When setting up this new system, the practice collaborated with the tech company to design intake forms for specific disease states, like headache, so the HPI would be most accurate. This allows providers to spend more meaningful time with patients, leaving more time for clarification and critical thinking, he said.

    For patients who may feel frustrated with the integration of more technology, Garms said it helps to incentivize them by explaining the benefits it has on their time.

    “As a selling point to the pushback of ‘I don’t want to use these things,’ that’s what the incentive is: they get their service faster, they’re spending time with the people they expected to spend time with and get what they needed at visit,” she said.

    For anyone looking to implement these types of AI into their practice, Garms and Tramontozzi said the first step is connecting with your EHR vendor. They often have a list of AI vendors they integrate with. They also suggested networking with colleagues who have implemented this type of technology. But the most crucial step is choosing technology that integrates with your EHR.

    “That’s the first barrier that you need to solve because you don’t want to pay extra for computer science engineers,” Tramontozzi said. “It has to be integrated.”

    Sources/Disclosures

    Collapse

    Source:

    Garms L, et al. ChatPMT: Ask the practice management expert. Presented at: American Academy of Neurology annual meeting; April 13-18, 2024; Denver.

    Disclosures:
    Garms and Tramontozzi report no relevant financial disclosures.

    Add topic to email alerts

    Receive an email when new articles are posted on

    Please provide your email address to receive an email when new articles are posted on .


    data-action=”subscribe”>
    Subscribe

    We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

    Back to Healio

  • Conservative Justices Stir Trouble for Republican Politicians on Abortion

    Conservative Justices Stir Trouble for Republican Politicians on Abortion

    Abortion opponents have maneuvered in courthouses for years to end access to reproductive health care. In Arizona last week, a win for the anti-abortion camp caused political blowback for Republican candidates in the state and beyond.

    The reaction echoed the response to an Alabama Supreme Court decision over in vitro fertilization just two months before.

    The election-year ruling by the Arizona Supreme Court allowing enforcement of a law from 1864 banning nearly all abortions startled Republican politicians, some of whom quickly turned to social media to denounce it.

    The court decision was yet another development forcing many Republicans legislators and candidates to thread the needle: Maintain support among anti-abortion voters while not damaging their electoral prospects this fall. This shifting power dynamic between state judges and state lawmakers has turned into a high-stakes political gamble, at times causing daunting problems, on a range of reproductive health issues, for Republican candidates up and down the ballot.

    “When the U.S. Supreme Court said give it back to the states, OK, well now the microscope is on the states,” said Jennifer Piatt, co-director of the Center for Public Health Law and Policy at Arizona State University’s Sandra Day O’Connor College of Law. “We saw this in Alabama with the IVF decision,” she said, “and now we’re seeing it in Arizona.”

    Multiple Republicans have criticized the Arizona high court’s decision on the 1864 law, which allows abortion only to save a pregnant woman’s life. “This decision cannot stand. I categorically reject rolling back the clock to a time when slavery was still legal and where we could lock up women and doctors because of an abortion,” state Rep. Matt Gress said in a video April 9. All four Arizona Supreme Court justices who said the long-dormant Arizona abortion ban could be enforced were appointed by former Gov. Doug Ducey, a Republican who in 2016 expanded the number of state Supreme Court justices from five to seven and cemented the bench’s conservative majority.

    Yet in a post the day of the ruling on the social platform X, Ducey said the decision “is not the outcome I would have preferred.”

    The irony is that the decision came after years of efforts by Arizona Republicans “to lock in a conservative majority on the court at the same time that the state’s politics were shifting more towards the middle,” said Douglas Keith, senior counsel at the left-leaning Brennan Center for Justice.

    All the while, anti-abortion groups have been pressuring Republicans to clearly define where they stand.

    “Whether running for office at the state or federal level, Arizona Republicans cannot adopt the losing ostrich strategy of burying their heads in the sand on the issue of abortion and allowing Democrats to define them,” Kelsey Pritchard, a spokesperson for Susan B. Anthony Pro-Life America, said in an emailed statement. “To win, Republicans must be clear on the pro-life protections they support, express compassion for women and unborn children, and contrast their position with the Democrat agenda.”

    Two months before the Arizona decision, the Alabama Supreme Court said frozen embryos from in vitro fertilization can be considered children under state law. The decision prompted clinics across the state to halt fertility treatments and caused a nationwide uproar over reproductive health rights. With Republicans feeling the heat, Alabama lawmakers scrambled to pass a law to shield IVF providers from prosecution and civil lawsuits “for the damage to or death of an embryo” during treatment.

    But when it comes to courts, Arizona lawmakers are doubling down: state Supreme Court justices are appointed by the governor but generally face voters every six years in retention elections. That could soon change. A constitutional amendment referred by the Arizona Legislature that could appear on the November ballot would eliminate those regular elections — triggering them only under limited circumstances — and allow the justices to serve as long as they exhibit “good behavior.” Effectively it would grant justices lifetime appointments until age 70, when they must retire.

    Even with the backlash against the Arizona court’s abortion decision, Keith said, “I suspect there aren’t Republicans in the state right now who are lamenting all these changes to entrench a conservative majority on the Supreme Court.”

    Meanwhile, abortion rights groups are trying to get a voter-led state constitutional amendment on the ballot that would protect abortion access until fetal viability and allow abortions afterward to protect the life or health of the pregnant person.

    State court decisions are causing headaches even at the very top of the Republican ticket. In an announcement in which he declined to endorse a national abortion ban, presumptive Republican presidential nominee Donald Trump on April 8 said he was “proudly the person responsible” for ending Roe v. Wade, which recognized a federal constitutional right to abortion before being overturned by the U.S. Supreme Court in 2022, and said the issue should be left to states. “The states will determine by vote or legislation, or perhaps both, and whatever they decide must be the law of the land,” he said. But just two days later he sought to distance himself from the Arizona decision. Trump also praised the Alabama Legislature for enacting the law aiming to preserve access to fertility treatments. “The Republican Party should always be on the side of the miracle of life,” he said.

    Recent court decisions on reproductive health issues in Alabama, Arizona, and Florida will hardly be the last. The Iowa Supreme Court, which underwent a conservative overhaul in recent years, on April 11 heard arguments on the state’s near-total abortion ban. Republican Gov. Kim Reynolds signed it into law in 2023 but it has been blocked in court.

    In Florida, there was disappointment all around after dueling state Supreme Court decisions this month that simultaneously paved the way for a near-total abortion ban and also allowed a ballot measure that would enshrine abortion rights in the state constitution to proceed.

    The Florida high court’s decisions were “simply unacceptable when five of the current seven sitting justices on the court were appointed by Republican Governor Ron DeSantis,” Andrew Shirvell, executive director of the anti-abortion group Florida Voice for the Unborn, said in a statement. “Clearly, grassroots pro-life advocates have been misled by elements within the ‘pro-life, pro-family establishment’ because Florida’s highest court has now revealed itself to be a paper tiger when it comes to standing-up to the murderous abortion industry.”

    Tension between state judicial systems and conservative legislators seems destined to continue given judges’ growing power over reproductive health access, Piatt said, with people on both sides of the political aisle asking: “Is this a court that is potentially going to give me politically what I’m looking for?”

  • California Health Workers May Face Rude Awakening With $25 Minimum Wage Law

    California Health Workers May Face Rude Awakening With $25 Minimum Wage Law

    SACRAMENTO, Calif. — Nearly a half-million health workers who stand to benefit from California’s nation-leading $25 minimum wage law could be in for a rude awakening if hospitals and other health care providers follow through on potential cuts to hours and benefits.

    A medical industry challenge to a new minimum wage ordinance in one Southern California city suggests layoffs and reductions in hours and benefits, including cuts to premium pay and vacation time, could be one result of a state law set to begin phasing in in June. However, some experts are skeptical of that possibility.

    The California Hospital Association brought a partly successful legal challenge to Inglewood’s $25 minimum wage ordinance, which barred employers from taking those sorts of steps to offset their higher costs.

    “Layoffs, reductions in premium pay rates, reductions in non-wage benefits, reductions in hours, and increased charges are consequences of an employer having less money to spend—which will necessarily be the case given the significant increase in spending on wages due to the minimum wage,” the association said in its lawsuit. Additional examples include reducing health coverage and charging for parking or work-related equipment.

    Inglewood voters approved the ordinance in November 2022, nearly a year before California legislators enacted a $25 minimum wage for health workers. Those statewide higher wages are to be phased in starting in June under California’s first-in-the-nation law, but Gov. Gavin Newsom has since said they are too expensive as the state faces a deficit estimated between $38 billion and $73 billion. It’s unclear if lawmakers will agree to a delay or take other steps to reduce the cost.

    U.S. District Judge Dale S. Fischer agreed with the hospital industry in a March 11 tentative ruling when he shot down the portion of Inglewood’s ordinance banning layoffs and clawbacks by employers, while allowing the rest of the ordinance to remain in effect. He gave the sides time to object to his preliminary decision, though none did.

    The California Hospital Association represents more than 400 hospitals and was a key backer of the state’s carefully crafted compromise law, which notably contains none of the employee safeguards included in the Inglewood ordinance.

    Spokesperson Jan Emerson-Shea said the association doesn’t know how providers will react once the state law takes effect. “We don’t have any insights,” she said.

    “The challenge for any health care organization is figuring out how to pay for the higher wages,” said Joanne Spetz, director of the Philip R. Lee Institute for Health Policy Studies at the University of California-San Francisco. “Since labor costs are the largest part of any health care organization’s costs, it’s hard to figure out how to reduce spending without looking at labor costs.”

    Providers can try to increase revenues by bargaining for higher reimbursements from commercial insurers, she said. Public hospitals, nursing homes, and community clinics get most of their money through Medi-Cal, the state’s Medicaid program.

    Providers could reduce the services they offer, pare back charity care, and cut or delay capital investments, Spetz said. In the long term, she expects some combination of spending cuts and revenue increases.

    Both the state law and local ordinance cover far more than doctors and nurses, with a definition of health worker that includes janitors, housekeepers, groundskeepers, security guards, food service workers, laundry workers, and clerical staff.

    The most recent estimate by the Health Care Program at the University of California-Berkeley Labor Center is that as many as 426,000 health workers would make an average of $6,400 extra in the law’s first year, a 19% average pay bump mainly benefiting lower-income workers of color and women. State finance officials project that well over 500,000 workers will benefit.

    Researchers didn’t include layoffs and other potential staffing and benefit reductions when they projected the state law’s costs and benefits, said Laurel Lucia, the program’s director. But she pointed to initial projections by hospitals, doctors, and business and taxpayer groups that the wage hike would cost $8 billion annually, thereby imperiling services and resulting in higher premiums and higher costs for state and local governments.

    “It seems like a contradiction to say this law’s going to cost billions of dollars while at the same time saying it’s going to reduce workers’ total compensation,” said Lucia, who projects a far lower price tag.

    She added that state finance officials had anticipated that Medi-Cal reimbursements would reflect the increased labor costs, while Medicare would eventually at least partially compensate for the higher labor costs.

    Michael Reich, chair of the Center on Wage and Employment Dynamics at UC Berkeley’s Institute for Research on Labor and Employment, and affiliated economist Justin Wiltshire recently argued that California’s new $20 minimum wage law for fast-food workers won’t result in mass layoffs and price increases, as some have predicted.

    Health care is much different than fast food, Reich acknowledged, but he argued for much the same positive result.

    “A higher minimum wage will make it easier and cheaper for hospitals to recruit and retain these workers. The cost savings, and the productivity benefits of more experienced workers, could offset much of the labor cost increase,” Reich said.

    The hospital association filed its lawsuit against Inglewood’s ordinance in July, while it was still opposing early versions of the statewide minimum wage legislation. Among many other provisions, the statewide law put on hold an initiative to cap hospital executives’ salaries in Los Angeles.

    The hospital association’s legal challenge referenced in part layoffs and reduced working hours imposed by Centinela Hospital Medical Center after Inglewood’s ordinance took effect.

    But Centinela said the reduction was entirely unrelated to the ordinance and that all staff were offered alternate positions, which many accepted.

    “Centinela Hospital also has since added many more jobs in new clinical positions above minimum wage scale,” the hospital said in a statement.

    Service Employees International Union-United Healthcare Workers West, the prime backer of both the local ordinance and the statewide law, sued the hospital in April 2023 alleging that it cut workers’ hours to offset the higher minimum wage. The case is still pending.

    The union did not respond to repeated requests for comment.

    In a court filing, however, the union and city of Inglewood said similar employer restrictions in previous minimum wage laws have survived.

    The ordinance “merely sets the backdrop for collective bargaining negotiations,” and does not bar employers from locking out employees or hiring replacement workers during a strike. Employers can still lay off workers or reduce their hours, they said, so long as they don’t do so to fund the higher minimum wage.

    But Fischer agreed with the hospital association that layoffs and reductions in employees’ total compensation packages are “obvious responses by an employer to rising compensation costs.”

    Restricting employers’ options would violate federal labor relations rules, he said.

    “The minimum wage an employer has to pay its employees will invariably affect the total amount of compensation it is able or willing to pay,” he wrote “This will then invariably affect the number of employees it can retain and the number of hours those employees will be scheduled to work.”

    This article was produced by KFF Health News, which publishes California Healthline, an editorially independent service of the California Health Care Foundation. 

  • ‘Shorter is better’ message slow to reach pediatrics

    ‘Shorter is better’ message slow to reach pediatrics

    April 15, 2024

    4 min read

    Add topic to email alerts

    Receive an email when new articles are posted on

    Please provide your email address to receive an email when new articles are posted on .


    data-action=”subscribe”>
    Subscribe

    We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

    Back to Healio

    Key takeaways:

    • Studies have shown that shorter antibiotic courses are just as effective as longer ones for some infections.
    • In pediatrics, strep pharyngitis, sinusitis and ear infections are targets for improvement.

    Many studies have shown that shorter courses of antibiotic therapy are just as effective as longer ones for certain infections, including those that impact children. The idea is commonly referred to using the mantra “shorter is better.”

    In an article published in the Journal of the Pediatric Infectious Diseases Society, physicians outlined the evidence supporting shorter antibiotic courses for three common pediatric upper respiratory tract infections and discussed the impact that academic imprinting has on prescribing practices in pediatrics.

    We spoke with two of the authors — Rana E. El Feghaly, MD, MSCI, director of the outpatient antibiotic stewardship program at Children’s Mercy Kansas City, and Nicole M. Poole MD, MPH, associate medical director of the antimicrobial stewardship program at Children’s Hospital Colorado — to learn more.

    Healio: Do you think the message that long antibiotic courses may not be necessary for many common illnesses has been received by most pediatricians?

    Poole: The short answer is no, because antibiotics continue to be prescribed for long durations for many common illnesses. A challenge is that guidelines come out infrequently and new, more current research is available that is sometimes difficult for clinicians in a busy practice to keep up with. Overall, clinicians are open to prescribing shorter durations, which is why we thought it was so important to review the data in one article and be able to discuss how we can recalibrate what we consider default durations for these very common illnesses.

    El Feghaly: I am not sure the message has been shared with most pediatricians yet! Studies have shown that prescribers and parents do not have reservations about shorter courses of antibiotics if they know they would be as effective as longer courses. This is where antimicrobial stewards can focus their efforts because it seems to me to be a low-hanging fruit for quality improvement efforts. In fact, investigators in Chicago found that merely changing the medical record’s preset durations allowed for substantial improvement in antibiotic duration use.

    Healio: In the paper, you specifically mention group A strep pharyngitis, acute otitis media and acute bacterial rhinosinusitis. There are other illnesses — like community-acquired pneumonia (CAP) and UTI — that also may be treated with shorter than recommended courses. Why did you focus on those three?

    El Feghaly: You are correct: The list we included is not exhaustive, and studies suggest that 5-day courses for UTI and CAP would be absolutely safe in children, but focusing on the three most common upper respiratory infections that result in antibiotic prescriptions made good sense as an initial effort.

    Nicole Poole

    Poole: Strep pharyngitis, sinusitis and ear infections are high-impact targets for improvement to decrease unnecessary antibiotic exposure in millions of children nationwide.

    El Feghaly: Maybe we should be writing a “Give me 5” 2.0 article to address UTI and CAP! [Editor’s note: The title of the paper is, “‘Give Me Five’: The Case for 5 Days of Antibiotics as the Default Duration for Acute Respiratory Tract Infections.”]

    Healio: Can you explain academic imprinting and the effect it has on prescribing?

    Poole: Academic imprinting is a strong adherence to — and a bit of fear about straying away from — what’s already established in medical practice, often based on early studies. For antibiotic prescribing, the focus wasn’t initially on how long you should take them or the risks of antibiotic overuse, and long durations were chosen. But since those studies, we have seen many changes in common infections — such as shifts in disease epidemiology after effective vaccine campaigns and understanding the many harms of antibiotic overuse.

    We have also identified opportunities to increase the quality and safety of our clinical practices through large observational and smaller prospective studies. But because of academic imprinting, we often stick to outdated approaches because of our high academic standards. The burden of proof to change practice typically rests on rigorous multicentered prospective randomized studies that would require large and often unattainable participant numbers to statistically measure rare outcomes.

    The thing is, these foundational studies that set the standard often had less rigorous methods than we tend to accept now, yet they still dictate practice because it is how we’ve always done it. To move medicine forward, we must challenge these ingrained practices.

    Healio: What are some other reasons that guidelines haven’t necessarily changed for some of these conditions, or that prescribers may still opt for longer durations of antibiotics despite evidence showing that shorter courses work?

    El Feghaly: The process of updating national guidelines is a collaborative effort that requires extensive review of the literature that can be undertaken only every few years, whereas new investigations continue to be published at a relatively fast pace. The guidelines we mention in our article are all over 10 years old. We have no doubt that when the new guidelines come out for these three diagnoses, they will include newer data, and we hope they will recommend shorter durations.

    Poole: As for prescribers, I think they do often rely on national guidelines, and there can be a hesitation to prescribing differently, even with the understanding that guidelines might be archived or outdated. Going back to academic imprinting, there are also beliefs that have been long held but not completely accurate, such as the historical belief that there is a serious need to finish all your antibiotics — which was often 10 to 14 days — to prevent antibiotic resistance.

    Prescribing short durations of antibiotics is a culture shift in our field in many ways, and I am grateful that many investigators have been studying how to push pediatrics forward for the benefit of our patients. We need to get the word out widely about current evidence so that prescribers feel empowered to provide the highest quality of care to their patient.

    As mentioned in the article, parents are very open to shorter durations of therapy and trust clinician recommendations. When parents understand that fewer days of antibiotic are effective and safer, this could also help propel the “shorter is better” practice of antibiotic prescribing. We shouldn’t overlook the significance for parents of reducing the task of giving medication to a 2-year-old by 5 days.

    El Feghaly: Although outpatient antimicrobial stewardship is getting a little more attention recently, it is still not where it needs to be in terms of resource allocation and support. Knowing that most antibiotics are prescribed in ambulatory settings, we need to do better! But if you are an antibiotic steward with no significant time or staff support for outpatient efforts, know that focusing those limited resources to duration may take you a long way! Also, resources other than guidelines are available on multiple platforms, such as clinical pathways from large institutions. Prescribers can use these resources to help them use the most updated evidence-based information.

    References:

    El Feghaly RE, et al. J Pediatric Infect Dis Soc. 2024;doi:10.1093/jpids/piae034.

    Published by:
    infectious diseases in children

    Sources/Disclosures

    Collapse

    Source:

    Healio Interviews

    Disclosures:
    El Feghaly reports receiving grant funding from Merck. Poole reports no relevant financial disclosures. Please see the study for all other authors’ relevant financial disclosures.

    Add topic to email alerts

    Receive an email when new articles are posted on

    Please provide your email address to receive an email when new articles are posted on .


    data-action=”subscribe”>
    Subscribe

    We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

    Back to Healio

  • Particle Health says dispute with Epic not affecting most customers

    Particle Health says dispute with Epic not affecting most customers

    Joos Mind | Photodisc | Getty Images

    Particle Health said on Monday that the “vast majority” of its customers are still receiving records from medical software giant Epic Systems despite an ongoing dispute between the two companies over data-sharing practices.

    Epic’s software supports more than 300 million patient records, and Particle acts like a middleman that helps health-care organizations access the data they need. Both companies belong to an interoperability network called Carequality, which facilitates the exchange of patient information on a large scale.

    On March 21, Epic filed a formal dispute with Carequality citing concerns that Particle and its participant organizations “might be inaccurately representing the purpose associated with their record retrievals.” To join the Carequality network, organizations must be approved and abide by “Permitted Purposes,” generally having to do with treatment, for the exchange of patient records.

    Patient data is protected by a federal law called the Health Insurance Portability and Accountability Act, or HIPAA, which requires a patient’s consent or knowledge for third-party access.

    Particle said in a release Monday that while Epic “indiscriminately stopped responding” to data requests from some of its customers because of the dispute, most clients were not affected. The company said it’s been pressing Epic to restore connection to impacted customers, and many are already back to normal.

    “While there is an ongoing dispute between Epic and Particle Health, related to three specific customers, the significant majority of Particle Health customers impacted by Epic’s actions were not in any way related to this dispute,” the company said in the release.

    In a statement to CNBC on Monday, Epic said it discovered that some Particle customers were accessing patient medical records by “falsely claiming to be treating them as patients.” Epic said that after a review, its customers asked the company to prevent “a small number” of groups from using Particle’s Carequality connection to access their data.

    “This violates the guidelines and spirit of Carequality, which was established to advance interoperability to improve treatment for patients,” Epic said in the statement.

    Epic said its customers have asked Particle to provide more information about how these organizations are using medical records before it restores access.

    Particle CEO Jason Prestinario said in his company’s release that the startup will address the dispute with Epic through official procedural channels.

    WATCH: Insurer stocks fall on Medicare rates